Milestone Pharmaceuticals Files 8-K
Ticker: MIST · Form: 8-K · Filed: Apr 8, 2024 · CIK: 1408443
Sentiment: neutral
Topics: 8-K, filing, financials
TL;DR
Milestone Pharma filed an 8-K, likely containing financial updates and other events. Keep an eye out for details.
AI Summary
Milestone Pharmaceuticals Inc. filed an 8-K on April 8, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about new events, financial figures, or material agreements, but serves as a notification of these categories being addressed.
Why It Matters
This 8-K filing indicates that Milestone Pharmaceuticals Inc. is providing updates or disclosures related to its financial statements and other significant events, which is important for investors to monitor company activities.
Risk Assessment
Risk Level: low — The filing is a standard 8-K notification without specific material disclosures, indicating no immediate new risks or opportunities.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- April 8, 2024 (date) — Date of earliest event reported
FAQ
What specific "Other Events" are being reported by Milestone Pharmaceuticals Inc. in this 8-K filing?
The filing does not specify the nature of the "Other Events" beyond listing it as an item information category.
Are there any new financial statements or exhibits included with this 8-K filing?
The filing lists "Financial Statements and Exhibits" as an item information category, but the specific content of these is not detailed in the provided text.
What is the principal executive office address for Milestone Pharmaceuticals Inc.?
The principal executive offices are located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, CA H4M 2X6.
When was Milestone Pharmaceuticals Inc. incorporated or organized?
The filing indicates the state of incorporation is "Québec" and the organization name is "03 Life Sciences", but a specific incorporation date is not provided.
What is the Commission File Number for Milestone Pharmaceuticals Inc.?
The Commission File Number for Milestone Pharmaceuticals Inc. is 001-38899.
Filing Stats: 445 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-04-08 16:38:37
Filing Documents
- tm2411306d1_8k.htm (8-K) — 25KB
- tm2411306d1_ex99-1.htm (EX-99.1) — 15KB
- tm2411306d1_ex99-1img001.jpg (GRAPHIC) — 16KB
- 0001104659-24-044767.txt ( ) — 241KB
- mist-20240408.xsd (EX-101.SCH) — 3KB
- mist-20240408_lab.xml (EX-101.LAB) — 33KB
- mist-20240408_pre.xml (EX-101.PRE) — 22KB
- tm2411306d1_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On April 8, 2024, Milestone Pharmaceuticals Inc. issued a press release announcing new clinical data demonstrating real-world application of etripamil for conversion of paroxysmal supraventricular tachycardia. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-Kand is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press release, dated April 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MILESTONE PHARMACEUTICALS INC. Date: April 8, 2024 By: /s/ Amit Hasija Amit Hasija Chief Financial Officer Principal Financial Officer